Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Development
Studies from Food & Drug Administration in the area of drug development published
May 18th, 2008
Current study results from the report, 'Are literature references sufficient for dose recommendations' An FDA case study of efavirenz and rifampin,' have been published. "One of the numerous regulatory functions of the Food and Drug Administration (FDA) is the evaluation of drug-drug interactions and the determination of appropriate dose adjustments, if necessary, to ensure the safe and effective use of medications. The FDA considers several data sources when determining the significance of drug-drug interactions," investigators in the United States report. "The majority of dose adjustment recommendations are based on specific drug-drug interactions studies. The FDA...
Source: Medical Letter on the CDC & FDA (2008-05-18)
|
